By Amira McKee

Shares of BioAge Labs climbed after the biopharmaceutical company said it received positive interim data from a continuing clinical trial evaluating its oral drug for patients with cardiovascular risk factors.

The stock recently rose 15%, to $16.08, in Monday trading. Shares have more than tripled in the past year.

The Emeryville, Calif., company's lead product candidate, BGE-102, is designed to counter age-related inflammation, which has been implicated in a range of diseases including cardiovascular disease, neurodegeneration and metabolic disorders. The drug inhibits NLRP3, which the company said is the driver of such inflammation.

The first BGE-102 cohort completed in obese individuals demonstrated rapid and profound reduction in inflammatory markers, the company said. On day 14 of treatment, the company said 93% of participants reached levels of blood inflammation below the clinically recognized threshold for reduced cardiovascular risk.

"We are very encouraged by these results, which support the potential for BGE-102 to deliver injectable-like inflammation reduction in an oral therapy designed for primary care, the clinical setting where most cardiovascular risk is managed and where oral medicines are preferred by patients and physicians," said Kristen Fortney, chief executive officer and co-founder of BioAge Labs.

Full Phase 1 data, including additional testing cohorts, is anticipated in the first half of 2026, the company said. A Phase 2a study is also on track to initiate in the first half of 2026, it added.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

January 12, 2026 12:10 ET (17:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.